600056 中国医药
已收盘 03-05 15:00:00
资讯
新帖
简况
中国医药（600056）披露子公司获得米诺地尔搽剂药品补充申请批准通知书，3月5日股价上涨0.58%
证券之星 · 03-05 22:36
中国医药（600056）披露子公司获得米诺地尔搽剂药品补充申请批准通知书，3月5日股价上涨0.58%
每周股票复盘：中国医药（600056）子公司获药品注册证书
证券之星 · 03-01
每周股票复盘：中国医药（600056）子公司获药品注册证书
中国医药（600056）披露为控股公司提供担保公告，2月27日股价上涨0.28%
证券之星 · 02-27
中国医药（600056）披露为控股公司提供担保公告，2月27日股价上涨0.28%
中国医药（600056）披露子公司获得注射用磷酸特地唑胺药品注册证书，2月25日股价上涨0.47%
证券之星 · 02-25
中国医药（600056）披露子公司获得注射用磷酸特地唑胺药品注册证书，2月25日股价上涨0.47%
中国医药最新公告：子公司康力药业获得注射用磷酸特地唑胺药品注册证书
证券之星 · 02-25
中国医药最新公告：子公司康力药业获得注射用磷酸特地唑胺药品注册证书
中国医药最新公告：子公司天方药业获得富马酸伏诺拉生片药品注册证书
证券之星 · 02-09
中国医药最新公告：子公司天方药业获得富马酸伏诺拉生片药品注册证书
中国医药(600056.SH)子公司达比加群酯胶囊获得药品注册证书
智通财经网 · 02-02
中国医药(600056.SH)子公司达比加群酯胶囊获得药品注册证书
每周股票复盘：中国医药（600056）现金收购则正医药25亿元
证券之星 · 02-01
每周股票复盘：中国医药（600056）现金收购则正医药25亿元
中国医药（600056）披露子公司获得药品补充申请批准通知书，1月29日股价下跌1.52%
证券之星 · 01-29
中国医药（600056）披露子公司获得药品补充申请批准通知书，1月29日股价下跌1.52%
中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业
智通财经 · 01-22
中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业
国家医保局助推药械出海；减肥神药价格大跳水
21世纪经济报道 · 01-19
国家医保局助推药械出海；减肥神药价格大跳水
摩根士丹利邢自强：2040年将迎来中国医药界的DeepSeek时刻
睿见Economy · 01-15
摩根士丹利邢自强：2040年将迎来中国医药界的DeepSeek时刻
里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业
智通财经 · 01-14
里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业
中国医药(600056.SH)获准发行不超20亿元公司债券
智通财经 · 01-12
中国医药(600056.SH)获准发行不超20亿元公司债券
每周股票复盘：中国医药（600056）子公司获尼麦角林片注册证
证券之星 · 01-11
每周股票复盘：中国医药（600056）子公司获尼麦角林片注册证
中国医药（600056）披露子公司获得药品注册证书，1月8日股价上涨0.38%
证券之星 · 01-08
中国医药（600056）披露子公司获得药品注册证书，1月8日股价上涨0.38%
中国医药(600056.SH)子公司获得尼麦角林片药品注册证书
智通财经网 · 01-08
中国医药(600056.SH)子公司获得尼麦角林片药品注册证书
中国医药（600056）公司公告子公司收到《税务事项通知书》暨补缴税款相关事项，12月31日股价上涨0.29%
证券之星 · 2025-12-31
中国医药（600056）公司公告子公司收到《税务事项通知书》暨补缴税款相关事项，12月31日股价上涨0.29%
中国医药最新公告：子公司天方药业的克拉霉素片通过仿制药一致性评价
证券之星 · 2025-12-31
中国医药最新公告：子公司天方药业的克拉霉素片通过仿制药一致性评价
中国医药最新公告：子公司需补缴税款及滞纳金约6521.78万元
证券之星 · 2025-12-31
中国医药最新公告：子公司需补缴税款及滞纳金约6521.78万元
加载更多
公司概况
公司名称：
中国医药健康产业股份有限公司
所属行业：
批发业
上市日期：
1997-05-15
主营业务：
中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是医药商业、医疗器械、国际贸易。公司入选药智网“2025中国化药研发实力排行榜TOP100”第50位；入选第七届CMC-CHINA中国制药工业博览会“2025中国制药工业TOP101”第87位。
发行价格：
7.02
{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"中国医药","latestPrice":10.38,"timestamp":1772694000000,"preClose":10.32,"halted":0,"volume":8701138,"delay":0,"changeRate":0.0058,"floatShares":1495000000,"shares":1496000000,"eps":0.3631,"marketStatus":"已收盘","change":0.06,"latestTime":"03-05 15:00:00","open":10.4,"high":10.42,"low":10.35,"amount":90359400,"amplitude":0.0068,"askPrice":10.38,"askSize":125,"bidPrice":10.37,"bidSize":350,"shortable":0,"etf":0,"ttmEps":0.3631,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":5,"adr":0,"adjPreClose":10.32,"symbolType":"stock","openAndCloseTimeList":[[1772674200000,1772681400000],[1772686800000,1772694000000]],"highLimit":11.35,"lowLimit":9.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"isCdr":false,"pbRate":1.31,"roa":"--","peRate":28.587166,"roe":"3.72%","epsLYR":0.358,"committee":0.064508,"marketValue":15527000000,"turnoverRate":0.0058,"status":0,"floatMarketCap":15522000000},"requestUrl":"/m/hq/s/600056","defaultTab":"news","newsList":[{"id":"2617252545","title":"中国医药（600056）披露子公司获得米诺地尔搽剂药品补充申请批准通知书，3月5日股价上涨0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617252545","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617252545?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:36","pubTimestamp":1772721376,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，中国医药报收于10.38元，较前一交易日上涨0.58%，最新总市值为155.27亿元。该股当日开盘10.4元，最高10.42元，最低10.35元，成交额达9035.94万元，换手率为0.58%。近日，中国医药发布公告称，其全资子公司天方药业有限公司收到国家药监局核准签发的两份米诺地尔搽剂《药品补充申请批准通知书》，该药品上市许可持有人由海南广升誉制药有限公司变更为天方药业。国内已有58家生产企业获批该药品，2024年全国销售额约4.47亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500039620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0028","600056","BK0082","BK0250","BK0185","BK0188","BK0175"],"gpt_icon":0},{"id":"2616843481","title":"每周股票复盘：中国医药（600056）子公司获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843481","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843481?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:13","pubTimestamp":1772302390,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，中国医药报收于10.66元，较上周的10.55元上涨1.04%。本周关注点公司公告汇总：子公司获注射用磷酸特地唑胺药品注册证书公司公告汇总：为控股公司江西南华提供10,000万元担保公司公告汇总关于子公司获得药品注册证书的公告中国医药全资子公司海南通用康力制药有限公司近日收到国家药监局核准签发的注射用磷酸特地唑胺《药品注册证书》。国家药监局于2024年9月受理该药品注册申请，截至目前累计投入约1274万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0082","BK0175","600056","BK0185","BK0250","BK0010"],"gpt_icon":0},{"id":"2614852427","title":"中国医药（600056）披露为控股公司提供担保公告，2月27日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614852427","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614852427?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:49","pubTimestamp":1772203750,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，中国医药报收于10.66元，较前一交易日上涨0.28%，最新总市值为159.46亿元。该股当日开盘10.61元，最高10.67元，最低10.57元，成交额达1.14亿元，换手率为0.72%。近日，中国医药健康产业股份有限公司发布《关于为控股公司提供担保的公告》。公司持有南华通用49%股权，表决权比例为51%，南华通用为公司控股子公司。截至公告日，公司及其控股子公司对外担保总额为30,000万元，占公司最近一期经审计净资产的2.54%，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0175","BK0188","BK0010","600056","BK0028","BK0250","BK0185"],"gpt_icon":0},{"id":"2614284035","title":"中国医药（600056）披露子公司获得注射用磷酸特地唑胺药品注册证书，2月25日股价上涨0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614284035","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614284035?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:49","pubTimestamp":1772030948,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，中国医药报收于10.67元，较前一交易日上涨0.47%，最新总市值为159.61亿元。该股当日开盘10.63元，最高10.73元，最低10.61元，成交额达1.04亿元，换手率为0.65%。中国医药近日披露公告，其全资子公司海南通用康力制药有限公司近日收到国家药监局核准签发的注射用磷酸特地唑胺《药品注册证书》。国家药监局于2024年9月受理该药品注册申请，截至目前累计投入约1274万元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0175","BK0188","BK0010","600056","BK0028","BK0250","BK0185"],"gpt_icon":0},{"id":"2614042567","title":"中国医药最新公告：子公司康力药业获得注射用磷酸特地唑胺药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2614042567","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614042567?lang=zh_cn&edition=full","pubTime":"2026-02-25 17:06","pubTimestamp":1772010412,"startTime":"0","endTime":"0","summary":"中国医药公告称，公司下属全资子公司海南通用康力制药有限公司收到国家药品监督管理局核准签发的一份注射用磷酸特地唑胺《药品注册证书》。该药品主要适用于治疗由革兰氏阳性菌敏感株引起的急性细菌性皮肤及皮肤软组织感染。截至公告披露日，该药品累计相关投入约1,274万元人民币。国内已有18个生产厂家通过或视同通过该药品的一致性评价。该药品2024年国内公立医院及公立基层医疗终端销售额约为116万元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500026799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0188","BK0082","BK0250","BK0010","BK0175","600056"],"gpt_icon":0},{"id":"2610634833","title":"中国医药最新公告：子公司天方药业获得富马酸伏诺拉生片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2610634833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610634833?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:11","pubTimestamp":1770635475,"startTime":"0","endTime":"0","summary":"中国医药公告称，公司下属全资子公司天方药业收到国家药监局核准签发的两份富马酸伏诺拉生片《药品注册证书》。截至公告披露日，国内已有39家生产企业获得该药品批件。2024年中国三大终端六大市场该药品销售额约为7.74亿元，2025年前三季度约为7.78亿元。本次获得富马酸伏诺拉生片制剂批件，将进一步夯实公司原料制剂一体化发展战略，有利于丰富公司产品线矩阵，完善产品布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900027184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0082","BK0028","BK0010","BK0188","BK0250","BK0175","BK0185"],"gpt_icon":0},{"id":"2608851054","title":"中国医药(600056.SH)子公司达比加群酯胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851054","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851054?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:55","pubTimestamp":1770022529,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药 发布公告，近日，公司下属全资子公司天方药业有限公司收到国家药品监督管理局核准签发的两份达比加群酯胶囊《药品注册证书》，规格：150mg、110mg。达比加群酯属于直接凝血酶抑制剂，主要用于减少非瓣膜性心房颤动的中风和全身性栓塞风险、治疗深静脉血栓形成和肺栓塞、降低深静脉血栓形成和肺栓塞复发的风险、髋关节置换手术后深静脉血栓形成和肺栓塞的预防。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600056","BK0028","BK0082","BK0185","BK0010","BK0188","BK0175","BK0250"],"gpt_icon":0},{"id":"2608072060","title":"每周股票复盘：中国医药（600056）现金收购则正医药25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072060","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072060?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:05","pubTimestamp":1769882719,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，中国医药报收于10.87元，较上周的10.74元上涨1.21%。本周，中国医药1月28日盘中最高价报11.51元。本周关注点机构调研要点：中国医药拟以25亿元现金收购则正医药，资金来源于经营结余和自筹。截至目前，国内共有6家企业通过或视同通过该药品一致性评价。三洋药业2024年该药品销售额约1,665万元，2025年约1,170万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK1574","BK0188","159938","600056","BK0028","BK0010","BK0250","BK1161","BK0082","BK1515","BK0185","09939"],"gpt_icon":0},{"id":"2607035480","title":"中国医药（600056）披露子公司获得药品补充申请批准通知书，1月29日股价下跌1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607035480","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607035480?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:30","pubTimestamp":1769697038,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，中国医药报收于11.04元，较前一交易日下跌1.52%，最新总市值为165.15亿元。近日，中国医药发布公告称，其全资子公司海南通用三洋药业有限公司收到国家药监局核准签发的两份注射用赖氨匹林《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。截至目前，国内共有6家企业通过或视同通过该药品一致性评价。三洋药业2024年该药品销售额约1,665万元，2025年约1,170万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","600056","BK0175","BK0028","BK0250","BK0010","BK0082","BK0188"],"gpt_icon":0},{"id":"2605546621","title":"中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2605546621","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605546621?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:30","pubTimestamp":1769070647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，国内医药企业国际化竞争力持续提升，新技术推动行业快速发展，国家政策鼓励创新药发展，看好相关创新药及制药企业。整体看，中国医药产业正站在全球化价值重估的起点，2026年将成为验证转型成效的关键节点。中国药企呈现全球化提速的格局。中国CXO企业凭借ADC、双抗、GLP-1等领域的一站式服务平台能力，完成从“中间供应商”到“全球创新赋能者”的跃升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK0250","BK0276","BK1191","BK1574","BK0010","BK0175","600056","BK0082","BK1161","BK0185","BK0188","BK0028","159992","601066","06978"],"gpt_icon":0},{"id":"2604083739","title":"国家医保局助推药械出海；减肥神药价格大跳水","url":"https://stock-news.laohu8.com/highlight/detail?id=2604083739","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604083739?lang=zh_cn&edition=full","pubTime":"2026-01-19 08:02","pubTimestamp":1768780979,"startTime":"0","endTime":"0","summary":"国家医保局助推药械出海；减肥神药价格大跳水","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601193622762816.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601193622762816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0188","BK0077","600056","BK0028","BK0010","BK0250","BK0251","688580","002317","BK0239","BK0082","BK0185"],"gpt_icon":0},{"id":"2603168601","title":"摩根士丹利邢自强：2040年将迎来中国医药界的DeepSeek时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168601","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603168601?lang=zh_cn&edition=full","pubTime":"2026-01-15 19:26","pubTimestamp":1768476360,"startTime":"0","endTime":"0","summary":"摩根士丹利中国首席经济学家邢自强指出，中国在科技创新领域正展现“星辰大海”式突破，三大核心优势：产业链集群、理工科人才红利、超大市场规模，这些难以被其他经济体复制。 他还指出，中国智能驾驶普及率全球领先、生物制药行业迎来爆发式增长，“我们测算，到了2040年，基本上美国FDA批准的新的创新药里，三分之一以上来自于中国，这也是中国医药界的DeepSeek时刻。”","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-01-15/doc-inhhkwct6264467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600056","MS"],"gpt_icon":0},{"id":"2603664448","title":"里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业","url":"https://stock-news.laohu8.com/highlight/detail?id=2603664448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603664448?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:20","pubTimestamp":1768371626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，展望2026年，相信对中国医疗板块而言，盈利交付将比估值扩张更为重要，料药明康德 有望跑赢同业。该行将药明康德列为中国CRO/CDMO行业的首选。该行维持药明康德“跑赢大市”评级及目标价143.4港元。相较同行，药明康德具备更强的盈利增长可见性：其2025年前三季度订单储备同比增长41%，远高于全球平均约14%，即使在地缘政治风险持续的背景下仍保持强劲增势。该行预计2026年药明康德的订单增速将继续领先全球同行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","LU0052750758.USD","LU1997244956.HKD","600056","603259","BK0175","CDMO","LU2125910500.SGD","BK0216","BK0082","BK1583","LU0708995583.HKD","LU0320764599.SGD","LU0456842615.SGD","LU2328871848.SGD","LU1808992512.USD","LU2242644610.SGD","LU1979443071.USD","LU1997245177.USD","BK0010","LU1046422090.SGD","BK4139","BK0188","LU2488822045.USD","BK0028","LU1969619763.USD","LU2495084118.USD","LU1997245094.SGD","02359","LU2045819591.USD","BK0185","BK1576","LU1934453819.USD","BK1141"],"gpt_icon":0},{"id":"2602851514","title":"中国医药(600056.SH)获准发行不超20亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602851514?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:18","pubTimestamp":1768213114,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司收到中国证券监督管理委员会《关于同意中国医药健康产业股份有限公司向专业投资者公开发行公司债券注册的批复》(证监许可〔2026〕21号)。据此批复，公司可以向专业投资者公开发行面值总额不超过20亿元公司债券。此批复自同意注册之日起24个月内有效，公司在注册有效期内可以分期发行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0250","BK0028","BK0188","BK0175","BK0010","BK0082","600056"],"gpt_icon":0},{"id":"2602535349","title":"每周股票复盘：中国医药（600056）子公司获尼麦角林片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535349","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535349?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:33","pubTimestamp":1768069987,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，中国医药报收于10.82元，较上周的10.33元上涨4.74%。本周，中国医药1月9日盘中最高价报10.84元。1月5日盘中最低价报10.3元。中国医药当前最新总市值161.85亿元，在医药商业板块市值排名6/32，在两市A股市值排名1284/5182。截至目前，国内已有包括三洋药业在内的十余家企业取得该药品批件。2024年该药品在中国三大终端六大市场的销售额约为34,972万元。此次获批有助于丰富公司产品线，完善神经系统用药领域布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0082","BK0188","BK0250","BK0010","BK0175","BK0028","BK0185"],"gpt_icon":0},{"id":"2601986733","title":"中国医药（600056）披露子公司获得药品注册证书，1月8日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601986733","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601986733?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:36","pubTimestamp":1767882979,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，中国医药报收于10.54元，较前一交易日上涨0.38%，最新总市值为157.67亿元。公司近日发布公告称，其全资子公司海南通用三洋药业有限公司获得国家药品监督管理局核准签发的尼麦角林片药品注册证书，药品注册分类为化学药品3类。截至目前，国内已有包括三洋药业在内的十余家企业取得该药品批件。2024年该药品在中国三大终端六大市场的销售额约为34,972万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800039234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0082","BK0175","600056","BK0185","BK0250","BK0010"],"gpt_icon":0},{"id":"2601351496","title":"中国医药(600056.SH)子公司获得尼麦角林片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601351496","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601351496?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:36","pubTimestamp":1767861387,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司海南通用三洋药业有限公司(简称“三洋药业”)收到国家药品监督管理局核准签发的尼麦角林片《药品注册证书》。尼麦角林片主要用于改善由于脑梗塞后遗症引起的意欲低下;也适用于血管性痴呆，尤其在早期治疗时对认知、记忆等有改善，并能减轻疾病严重程度。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国医药(600056.SH)子公司获得尼麦角林片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0185","BK0188","BK0082","600056","BK0250","BK0010","BK0175"],"gpt_icon":0},{"id":"2595777642","title":"中国医药（600056）公司公告子公司收到《税务事项通知书》暨补缴税款相关事项，12月31日股价上涨0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777642","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777642?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:24","pubTimestamp":1767191063,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，中国医药报收于10.33元，较前一交易日上涨0.29%，最新总市值为154.52亿元。该股当日开盘10.32元，最高10.37元，最低10.27元，成交额达7810.71万元，换手率为0.51%。近日，中国医药发布公告称，公司全资子公司三洋药业和康力药业分别收到税务部门通知，需补缴税款及滞纳金。三洋药业补缴税款2,148.62万元，滞纳金约1,074.29万元；康力药业补缴税款2,128.26万元，滞纳金约1,170.61万元。合计补缴金额约6,521.78万元，不涉及行政处罚。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","600056","BK0082","BK0010","BK0188","BK0250","BK0028","BK0175"],"gpt_icon":0},{"id":"2595777822","title":"中国医药最新公告：子公司天方药业的克拉霉素片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777822","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777822?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:11","pubTimestamp":1767175864,"startTime":"0","endTime":"0","summary":"中国医药公告称，公司下属全资子公司天方药业收到国家药监局核准签发的克拉霉素片《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。截至公告披露日，除天方药业外，国内已有10多家企业通过或视同通过该药品的一致性评价。该药品2024年国内公立医院及公立基层医疗终端销售额约为4.07亿元。天方药业的克拉霉素片通过一致性评价，有助于提升该药品的市场竞争力，但未来可能存在销售不达预期等风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","BK0188","BK0185","BK0082","600056","BK0250","BK0010"],"gpt_icon":0},{"id":"2595778243","title":"中国医药最新公告：子公司需补缴税款及滞纳金约6521.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778243?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:09","pubTimestamp":1767175784,"startTime":"0","endTime":"0","summary":"中国医药(600056.SH)公告称，公司下属全资子公司海南通用三洋药业有限公司和海南康力药业有限公司分别收到《税务事项通知书》，需补缴税款及滞纳金约6521.78万元。补缴税款和滞纳金将计入公司2025年当期损益，预计影响公司2025年度净利润6521.78万元。本次补缴税款事项不会影响公司的正常经营。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0185","BK0010","BK0175","BK0188","BK0028","BK0082","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772753385230,"stockEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":-0.0371},{"period":"3month","weight":-0.0503},{"period":"6month","weight":-0.0346},{"period":"1year","weight":-0.0036},{"period":"ytd","weight":0.0048}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"139689人(较上一季度增加0.69%)","perCapita":"10704股","listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","registeredCapital":"149587万元","survey":" 中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是医药商业、医疗器械、国际贸易。公司入选药智网“2025中国化药研发实力排行榜TOP100”第50位；入选第七届CMC-CHINA中国制药工业博览会“2025中国制药工业TOP101”第87位。","listedPrice":7.02},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国医药,600056,中国医药股票,中国医药股票老虎,中国医药股票老虎国际,中国医药行情,中国医药股票行情,中国医药股价,中国医药股市,中国医药股票价格,中国医药股票交易,中国医药股票购买,中国医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}